Literature DB >> 17242276

Defining the cellular phenotype of "ankyrin-B syndrome" variants: human ANK2 variants associated with clinical phenotypes display a spectrum of activities in cardiomyocytes.

Peter J Mohler1, Solena Le Scouarnec, Isabelle Denjoy, John S Lowe, Pascale Guicheney, Lise Caron, Iwona M Driskell, Jean-Jacques Schott, Kris Norris, Antoine Leenhardt, Richard B Kim, Denis Escande, Dan M Roden.   

Abstract

BACKGROUND: Mutations in the ankyrin-B gene (ANK2) cause type 4 long-QT syndrome and have been described in kindreds with other arrhythmias. The frequency of ANK2 variants in large populations and molecular mechanisms underlying the variability in the clinical phenotypes are not established. More importantly, there is no cellular explanation for the range of severity of cardiac phenotypes associated with specific ANK2 variants. METHODS AND
RESULTS: We performed a comprehensive screen of ANK2 in populations (control, congenital arrhythmia, drug-induced long-QT syndrome) of different ethnicities to discover unidentified ANK2 variants. We identified 7 novel nonsynonymous ANK2 variants; 4 displayed abnormal activity in cardiomyocytes. Including the 4 new variants, 9 human ANK2 loss-of-function variants have been identified. However, the clinical phenotypes associated with these variants vary strikingly, from no obvious phenotype to manifest long-QT syndrome and sudden death, suggesting that mutants confer a spectrum of cellular phenotypes. We then characterized the relative severity of loss-of-function properties of all 9 nonsynonymous ANK2 variants identified to date in primary cardiomyocytes and identified a range of in vitro phenotypes, including wild-type, simple loss-of-function, and severe loss-of-function activity, seen with the variants causing severe human phenotypes.
CONCLUSIONS: We present the first description of differences in cellular phenotypes conferred by specific ANK2 variants. We propose that the various degrees of ankyrin-B loss of function contribute to the range of severity of cardiac dysfunction. These data identify ANK2 variants as modulators of human arrhythmias, provide the first insight into the clinical spectrum of "ankyrin-B syndrome," and reinforce the role of ankyrin-B-dependent protein interactions in regulating cardiac electrogenesis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17242276     DOI: 10.1161/CIRCULATIONAHA.106.656512

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  70 in total

1.  Ankyrin-B reduction enhances Ca spark-mediated SR Ca release promoting cardiac myocyte arrhythmic activity.

Authors:  Emmanuel Camors; Peter J Mohler; Donald M Bers; Sanda Despa
Journal:  J Mol Cell Cardiol       Date:  2012-03-03       Impact factor: 5.000

2.  From Fifth Business to Protagonist: the complex roles of ion channel anchors in cardiac arrhythmia.

Authors:  Crystal F Kline; Peter J Mohler
Journal:  Drug Discov Today Dis Models       Date:  2009-09-01

Review 3.  Defining a new paradigm for human arrhythmia syndromes: phenotypic manifestations of gene mutations in ion channel- and transporter-associated proteins.

Authors:  Michael J Ackerman; Peter J Mohler
Journal:  Circ Res       Date:  2010-08-20       Impact factor: 17.367

4.  Defining new insight into atypical arrhythmia: a computational model of ankyrin-B syndrome.

Authors:  Roseanne M Wolf; Colleen C Mitchell; Matthew D Christensen; Peter J Mohler; Thomas J Hund
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-08-20       Impact factor: 4.733

5.  Ankyrin-B protein in heart failure: identification of a new component of metazoan cardioprotection.

Authors:  Farshid Kashef; Jingdong Li; Patrick Wright; Jedidiah Snyder; Faroug Suliman; Ahmet Kilic; Robert S D Higgins; Mark E Anderson; Philip F Binkley; Thomas J Hund; Peter J Mohler
Journal:  J Biol Chem       Date:  2012-07-09       Impact factor: 5.157

Review 6.  Drug-induced long QT syndrome.

Authors:  Prince Kannankeril; Dan M Roden; Dawood Darbar
Journal:  Pharmacol Rev       Date:  2010-12       Impact factor: 25.468

Review 7.  Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges.

Authors:  Russell A Wilke; Debbie W Lin; Dan M Roden; Paul B Watkins; David Flockhart; Issam Zineh; Kathleen M Giacomini; Ronald M Krauss
Journal:  Nat Rev Drug Discov       Date:  2007-11       Impact factor: 84.694

8.  Regulation of the ankyrin-B-based targeting pathway following myocardial infarction.

Authors:  Thomas J Hund; Patrick J Wright; Wen Dun; Jedidiah S Snyder; Penelope A Boyden; Peter J Mohler
Journal:  Cardiovasc Res       Date:  2008-12-14       Impact factor: 10.787

9.  A dynamic pathway for calcium-independent activation of CaMKII by methionine oxidation.

Authors:  Jeffrey R Erickson; Mei-ling A Joiner; Xiaoqun Guan; William Kutschke; Jinying Yang; Carmine V Oddis; Ryan K Bartlett; John S Lowe; Susan E O'Donnell; Nukhet Aykin-Burns; Matthew C Zimmerman; Kathy Zimmerman; Amy-Joan L Ham; Robert M Weiss; Douglas R Spitz; Madeline A Shea; Roger J Colbran; Peter J Mohler; Mark E Anderson
Journal:  Cell       Date:  2008-05-02       Impact factor: 41.582

Review 10.  Genetics of long QT syndrome.

Authors:  David J Tester; Michael J Ackerman
Journal:  Methodist Debakey Cardiovasc J       Date:  2014 Jan-Mar
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.